Detalhe da pesquisa
1.
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.
Clin Infect Dis
; 58(3): 413-22, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24145879
2.
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Antimicrob Agents Chemother
; 55(9): 4290-4, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21670182
3.
Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.
J Pediatric Infect Dis Soc
; 10(2): 201-204, 2021 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32448902
4.
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Pediatr Infect Dis J
; 40(5): 446-452, 2021 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33464021
5.
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
AIDS
; 35(9): 1413-1421, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33831904
6.
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
J Pediatric Infect Dis Soc
; 9(2): 159-165, 2020 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30951600
7.
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).
J Acquir Immune Defic Syndr
; 84(1): 70-77, 2020 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31913995
8.
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.
J Acquir Immune Defic Syndr
; 85(5): 626-634, 2020 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32925360
9.
Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
Pediatr Infect Dis J
; 28(2): 159-61, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19106779
10.
Sertraline Pharmacokinetics in HIV-Infected and Uninfected Children, Adolescents, and Young Adults.
Front Pediatr
; 7: 16, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30788337
11.
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Lancet HIV
; 5(12): e715-e722, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30527329
12.
A trial of three antiretroviral regimens in HIV-1-infected children.
N Engl J Med
; 350(24): 2471-80, 2004 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-15190139
13.
Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.
J Pediatric Infect Dis Soc
; 6(3): 294-296, 2017 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27103489
14.
Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.
PLoS One
; 12(10): e0186589, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29065172
15.
Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia.
Pediatr Infect Dis J
; 36(1): 53-60, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27749649
16.
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.
Pediatr Infect Dis J
; 35(12): 1333-1335, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27583590
17.
Rilpivirine Pharmacokinetics Without and With Darunavir/Ritonavir Once Daily in Adolescents and Young Adults.
Pediatr Infect Dis J
; 35(9): e271-4, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27187753
18.
Pharmacokinetics of Once-Daily Darunavir/Ritonavir With and Without Etravirine in Human Immunodeficiency Virus-Infected Children, Adolescents, and Young Adults.
J Pediatric Infect Dis Soc
; 5(2): 131-7, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27199469
19.
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Pediatr Infect Dis J
; 34(2): 162-7, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25232777
20.
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.
J Pediatric Infect Dis Soc
; 4(4): e76-83, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26582887